Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
This is a multicentric, phase II and open label study.75 patients are expected to be
randomized in 35 centers. The main objective is to assess the efficacy and safety of Afatinib
-cetuximab combo versus cetuximab alone in treatment of patients with refractory wtKRAS
metastatic colorectal cancer.